Danish drugmaker Novo Nordisk plans to sell its obesity treatments through the platform of Hims & Hers Health, ending a dispute between the two firms that recently escalated into a legal battle. <\/p>\n
<\/p>\n
Following the report, shares of Hims surged about 39% in after-hours trading, News.Az<\/a> reports, citing Reuters<\/a>.<\/p>\n The potential partnership comes nearly a month after Novo Nordisk sued Hims for alleged patent infringement. The lawsuit followed the U.S. telehealth company\u2019s launch, and later cancellation, of a $49 copy of Novo\u2019s obesity pill.<\/p>\n The U.S. Food and Drug Administration had also warned it could take action against Hims over the issue.<\/p>\n According to Bloomberg, the companies plan to announce the new partnership as early as Monday.<\/p>\n The dispute traces back to last year, when Novo Nordisk ended a short-lived arrangement that allowed its popular weight-loss drug Wegovy to be sold through the Hims platform. At the time, the pharmaceutical giant cited concerns over Hims\u2019 marketing practices and the continued sale of Wegovy copies.<\/p>\n In a statement, a Novo Nordisk<\/a> spokesperson said the company is \u201calways in conversation with companies that can help improve patient access to FDA-approved medicines.\u201d<\/p>\n Hims & Hers Health has not yet commented on the reported agreement.<\/p>\n The possible partnership highlights the growing demand for obesity treatments and the increasing role of telehealth platforms in expanding patient access to prescription medications.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n
<\/p>\n \u00a0<\/p>\n